Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Equity and Gender Issues Among Members of the Canadian Association of Gastroenterology.

Perera S, Bistritz L, Beaton MD.

J Can Assoc Gastroenterol. 2019 Dec;2(4):170-177. doi: 10.1093/jcag/gwy044. Epub 2018 Aug 28.

2.

Fall-related deaths among older adults in British Columbia: cause and effect of policy change.

Joshi A, Rajabali F, Turcotte K, Beaton MD, Pike I.

Inj Prev. 2019 Aug 30. pii: injuryprev-2019-043280. doi: 10.1136/injuryprev-2019-043280. [Epub ahead of print]

3.

Family members' experiences and management of resident-to-resident abuse in long-term residential care.

Baumbusch J, Puurveen G, Phinney A, Beaton MD, Leblanc ME.

J Elder Abuse Negl. 2018 Nov-Dec;30(5):385-401. doi: 10.1080/08946566.2018.1518179. Epub 2018 Sep 17.

PMID:
30222059
4.

Apixaban and Rosuvas--tatin Pharmacokinetics in Nonalcoholic Fatty Liver Disease.

Tirona RG, Kassam Z, Strapp R, Ramu M, Zhu C, Liu M, Schwarz UI, Kim RB, Al-Judaibi B, Beaton MD.

Drug Metab Dispos. 2018 May;46(5):485-492. doi: 10.1124/dmd.117.079624. Epub 2018 Feb 22.

PMID:
29472495
5.

Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial.

Joy TR, McKenzie CA, Tirona RG, Summers K, Seney S, Chakrabarti S, Malhotra N, Beaton MD.

World J Gastroenterol. 2017 Jan 7;23(1):141-150. doi: 10.3748/wjg.v23.i1.141.

6.

A Fibroblast Growth Factor 21-Pregnane X Receptor Pathway Downregulates Hepatic CYP3A4 in Nonalcoholic Fatty Liver Disease.

Woolsey SJ, Beaton MD, Mansell SE, Leon-Ponte M, Yu J, Pin CL, Adams PC, Kim RB, Tirona RG.

Mol Pharmacol. 2016 Oct;90(4):437-46. doi: 10.1124/mol.116.104687. Epub 2016 Aug 1.

PMID:
27482056
7.

Is vitamin e or ursodeoxycholic acid a valid treatment option for nonalcoholic fatty liver disease in 2016?

Beaton MD, Al-Judaibi B.

Saudi J Gastroenterol. 2016 May-Jun;22(3):169-70. doi: 10.4103/1319-3767.182462. No abstract available.

8.

Management of non-alcoholic fatty liver disease in 2015.

Malhotra N, Beaton MD.

World J Hepatol. 2015 Dec 28;7(30):2962-7. doi: 10.4254/wjh.v7.i30.2962. Review.

9.

Relationships between Endogenous Plasma Biomarkers of Constitutive Cytochrome P450 3A Activity and Single-Time-Point Oral Midazolam Microdose Phenotype in Healthy Subjects.

Woolsey SJ, Beaton MD, Choi YH, Dresser GK, Gryn SE, Kim RB, Tirona RG.

Basic Clin Pharmacol Toxicol. 2016 Apr;118(4):284-91. doi: 10.1111/bcpt.12492. Epub 2015 Oct 14.

10.

CYP3A Activity and Expression in Nonalcoholic Fatty Liver Disease.

Woolsey SJ, Mansell SE, Kim RB, Tirona RG, Beaton MD.

Drug Metab Dispos. 2015 Oct;43(10):1484-90. doi: 10.1124/dmd.115.065979. Epub 2015 Jul 31.

PMID:
26231377
11.

The Celiac Disease and Diabetes-Dietary Intervention and Evaluation Trial (CD-DIET) protocol: a randomised controlled study to evaluate treatment of asymptomatic coeliac disease in type 1 diabetes.

Mahmud FH, De Melo EN, Noordin K, Assor E, Sahota K, Davies-Shaw J, Cutz E, Somers G, Lawson M, Mack DR, Gallego P, McDonald C, Beaton MD, Bax K, Saibil F, Gilbert J, Kirsch S, Perkins BA, Cino M, Szentgyorgyi E, Koltin D, Parikh A, Mukerji G, Advani A, Lou O, Marcon MA.

BMJ Open. 2015 May 11;5(5):e008097. doi: 10.1136/bmjopen-2015-008097.

12.

Inflammation is not the cause of an elevated serum ferritin in non-alcoholic fatty liver disease.

Beaton MD, Chakrabarti S, Adams PC.

Ann Hepatol. 2014 May-Jun;13(3):353-6.

13.

Validation of volumetric and single-slice MRI adipose analysis using a novel fully automated segmentation method.

Addeman BT, Kutty S, Perkins TG, Soliman AS, Wiens CN, McCurdy CM, Beaton MD, Hegele RA, McKenzie CA.

J Magn Reson Imaging. 2015 Jan;41(1):233-41. doi: 10.1002/jmri.24526. Epub 2014 Jan 15.

PMID:
24431195
14.

Phase II clinical trial of phlebotomy for non-alcoholic fatty liver disease.

Beaton MD, Chakrabarti S, Levstik M, Speechley M, Marotta P, Adams P.

Aliment Pharmacol Ther. 2013 Apr;37(7):720-9. doi: 10.1111/apt.12255. Epub 2013 Feb 26.

15.
16.

Treatment of hyperferritinemia.

Beaton MD, Adams PC.

Ann Hepatol. 2012 May-Jun;11(3):294-300. Review.

17.

Transferrin saturation as a predictor of hepatic iron overload.

Adams PC, Beaton MD.

Liver Int. 2011 Feb;31(2):272-3. doi: 10.1111/j.1478-3231.2010.02335.x. Epub 2010 Aug 25. No abstract available.

PMID:
20738776
18.
19.

The myths and realities of hemochromatosis.

Beaton MD, Adams PC.

Can J Gastroenterol. 2007 Feb;21(2):101-4. Review.

20.

Supplemental Content

Loading ...
Support Center